(Mountain Standard Time)
All Day Arrivals
6:00 PM - 7:30 PM
Course Directors' Reception
6:45 AM - 7:45 AM
Breakfast
7:45 AM - 8:10 AM
The Year in Review
8:15 AM - 8:35 AM
Lanifibranor Data
8:35 AM - 8:55 AM
PNPLA3, HSD17B13 and Other Genetic Targets in MASH
8:55 AM - 9:15 AM
GLP-1 and Glucagon and/or GIP: Now and What's To Come
9:15 AM - 9:35 AM
A Deep Dive into Landscape of Thyroid Hormone Beta Receptor Agonists
9:35 AM - 9:50 AM
FGF21 as a Class: Recent Developments/Updates
9:50 AM - 10:10 AM
Panel Discussion
10:10 AM - 10:30 AM
Break - Exhibit Hall/Poster Viewing
10:30 AM - 10:45 AM
Where are we with Pharmacologic Interventions in Pediatric MASH?
10:45 AM - 11:00 AM
Specifics of Trial Design and Outcome Assessment in Children
11:00 AM - 11:15 AM
Heritability of MASLD and Genetics Approaches in MASLD
11:15 AM - 11:30 AM
New Insights into Event Rates for MALO in F4c
11:30 AM - 11:45 AM
Panel Discussion
11:45 AM - 11:55 AM
Oral Abstract Presentation
11:55 AM - 12:05 PM
Oral Abstract Presentation
12:05 PM - 1:15 PM
CME Symposium - Tentative
1:15 PM - 4:00 PM
Meetings, Poster Viewing and Self-Directed Learning
4:00 PM - 4:20 PM
Strategies for Muscle Preservation with Incretin Therapies
4:20 PM - 4:40 PM
Bone Health and Weight Losing Agents
4:40 PM - 5:00 PM
Sarcopenic Obesity: How to Diagnose and Why Should We Care?
5:00 PM - 5:20 PM
Myokine Signaling in Adipose Tissue: A New Target for MASLD?
5:20 PM - 5:35 PM
Panel Discussion
5:35 PM - 5:55 PM
Break
5:55 PM - 6:15 PM
HCC: A Blind Spot in MASLD Trials
6:15 PM - 6:35 PM
Cell Free DNA Based Biomarkers in MASH, Cirrhosis and HCC
6:35 PM - 6:55 PM
Mechanisms of Hepatic Carcinogenesis in MASLD
6:55 PM - 7:15 PM
Debate: Should We Include Recompensated MASH Cirrhosis Patients in Cirrhosis Trials?
7:15 PM - 7:30 PM
Panel Discussion
7:30 PM
Stephen A. Harrison Award for Excellence in MASH
7:30 PM
Faculty Dinner
6:45 AM - 8:00 AM
Breakfast
8:00 AM - 8:20 AM
Uncoupling of Fat and Lean Mass Loss During GLP-1 Induced Weight Reduction
8:20 AM - 8:40 AM
Liver and Healthy Aging and Longevity
8:40 AM - 9:00 AM
MASLD and Kidney Disease - a Reno-Hepatic Axis?
9:00 AM - 9:20 AM
MASLD and Heart Disease: Does a Fatty Liver Lead to a Broken Heart?
9:20 AM - 9:35 AM
Panel Discussion
9:35 AM - 9:50 AM
Break
9:50 AM - 10:10 AM
Assessing Outcomes: Ordinal Outcomes Estimands, Imputation Methods and Missing Data
10:10 AM - 10:30 AM
Emulation Trials and Observational Data: Can They Be Trusted When RCTs Are Not Feasible?
10:30 AM - 10:50 AM
Statistical Genetics and Prediction of Drug Efficacy (A Tool for Predictive Medicine)
10:50 AM - 11:10 AM
Assessing Responders Non-Invasively: What Would it Take in 2026?
11:10 AM - 11:25 AM
Panel Discussion
11:25 AM - 11:45 AM
Case Based Patient Journey: Nuances in Management
11:45 AM - 11:55 AM
Oral Abstract Presentation
11:55 AM - 12:05 PM
Oral Abstract Presentation
12:05 PM - 12:25 PM
How to Approach Two Approved Therapies: Step Up, Top Down or Tango?
12:25 PM - 4:00 PM
Meetings, Poster Viewing and Self-Directed Learning
4:00 PM - 4:20 PM
The Biology of Lipid Droplets and the Pathobiology of Steatohepatitis
4:20 PM - 4:40 PM
GDF15, an Emerging Metabolic Messenger
4:40 PM - 5:00 PM
Harnessing Glucagon Biology for the Treatment of MASLD
5:00 PM - 5:20 PM
The CAR-T Cell Promise for the Treatment of Liver Fibrosis
5:20 PM - 5:35 PM
The Top 5 Basic Papers of 2026
5:35 PM - 5:50 PM
Panel Discussion
5:50 PM - 6:05 PM
Break
6:05 PM - 6:15 PM
Eloralintide
6:15 PM - 6:25 PM
Cagrilintide
6:25 PM - 6:35 PM
Modulating HSD17B13 for Therapeutic Intervention
6:35 PM - 6:45 PM
CIDEB and PNPLA3
6:45 PM - 6:55 PM
The Promise of Oral GLP-1 Agonists
6:55 PM - 7:05 PM
Panel Discussion
7:05 PM
Wrap-Up
All Copyright © Reserved by MASH-TAG